The CMS CY 2027 final rule (CMS-4207-F), published April 2, 2026 and effective June 1, adds a Depression Screening and Follow-Up measure to the Part C Star Ratings. It is the first time behavioral health performance will directly drive quality bonus payments for roughly 33 million Medicare Advantage beneficiaries.
The scoring detail is where the difficulty sits. CMS displays screening and follow-up rates separately, then averages them into one score.
Key Takeaways
- Two rates averaged into one score means a plan at 90% screening and 60% follow-up records 75%, so the follow-up rate governs the result rather than the screening rate.
- 30 days is the documented follow-up window after a positive screen, against behavioral health networks most plans have not built to that throughput.
- 10% to 15% of primary care patients screen positive on validated instruments per USPSTF evidence, with Medicare-population estimates for depressive symptoms running 20% to 30%.
- $18.56 billion is CMS's projected 2027 to 2036 transfer to plan sponsors from the wider Star Ratings restructuring, which also removes 13 measures.
- 2027 measurement year, 2029 Star Ratings, CY 2031 bonus payments. Plans invest now and collect nearly five years later.
What the Measure Scores
The measure adapts the HEDIS Depression Screening and Follow-Up specification for the MA population, and splits into two components CMS tracks separately before combining.
Screening requires a validated instrument during the measurement year. The PHQ-2 asks two questions about depressed mood and anhedonia over the prior two weeks, scored 0 to 6, with 3 or above triggering further evaluation, usually the PHQ-9 covering the full DSM-5 criteria. Follow-up requires documented care within 30 days of a positive screen: pharmacotherapy, a behavioral health referral, further evaluation, or a documented plan in the record. A positive PHQ-2 followed by a negative PHQ-9 the same day counts, so screening and follow-up can both close in one visit.
| Milestone | Date | Actuarial Implication |
|---|---|---|
| CY 2027 final rule effective | June 1, 2026 | Plans must begin operational planning for screening workflows |
| Measurement year begins | January 1, 2027 | Depression screening data collection starts; baseline year for benchmarking |
| Measurement year ends | December 31, 2027 | Full year of screening and follow-up data available for actuarial analysis |
| 2029 Star Ratings published | October 2028 | First Star Ratings incorporating depression screening performance |
| Quality bonus payments | Contract Year 2031 | Bonus revenue impact from 2029 Stars reaches plan financials |
The measure does not arrive alone. The same rule removes 13 Star Ratings measures, three effective with the 2028 ratings and ten more with the 2029 ratings, the cycle where depression screening first appears. Most of the removed items are administrative and process categories where plans clustered at high performance with little variation, so the restructuring concentrates weight on clinical outcomes and patient experience, roughly 65% of the total against about 50% before.
The money attached is real. CMS projects a $18.56 billion transfer to plan sponsors over 2027 to 2036, about 0.21% of total Medicare payments to private plans, with roughly 63% of contracts unchanged and 37% moving in one direction or the other. Press Ganey's analysis suggests as much as 25% of contracts could lose half a star under the new methodology, putting an estimated $1.3 billion of bonus payments at risk.
The Follow-Up Rate Is the Constraint
Screening is a process problem and follow-up is a capacity problem, and the averaging puts the capacity problem in charge of the score.
A PHQ-2 takes under two minutes and a medical assistant can administer it inside an existing wellness visit. Follow-up requires a prescriber, a behavioral health appointment or a documented clinical plan within 30 days, each dependent on provider availability and care coordination most plans have not built to scale.
Run the arithmetic. A plan with 100,000 members screening at 85% covers 85,000 people. At a 12% positive rate that is roughly 10,200 members needing documented follow-up inside 30 days. A behavioral health network with capacity for 500 new patient appointments a month, generous in many markets, faces about 850 follow-up needs a month if screening is spread evenly across the year. The gap is structural rather than a scheduling failure.
Three routes close part of it without adding network capacity. Same-day PHQ-9 resolution satisfies the requirement when the fuller instrument comes back negative. A primary care prescriber initiating an antidepressant at the same visit satisfies it without any referral. Collaborative care, with a behavioral health care manager and consulting psychiatrist embedded in primary care, is reimbursable under Part B and keeps mild-to-moderate cases inside the practice.
The cost lands in three layers, and the middle one dominates. Adding a PHQ-2 to an existing wellness visit costs perhaps $2 to $5 per screen, and outreach to reach a 90% screening rate runs roughly $15 to $25 per member per year. Incremental behavioral health utilization is the larger figure: with 40% to 60% of positive screens belonging to members not previously receiving any behavioral health service, the new-episode cost works out to roughly $0.80 to $2.50 PMPM, or $960,000 to $3,000,000 a year on a 100,000-member plan, with another $0.30 to $0.75 PMPM of care coordination infrastructure behind it.
Screening Better Makes the Score Harder
The measure's two components pull against each other, and the plans doing the screening well are the ones that feel it.
CMS rewards a high screening rate, and every additional screen that comes back positive enters the denominator of the follow-up component. A plan screening 95% of its population identifies more positive cases than one at 70% even where underlying prevalence is identical, and each of those cases needs a documented disposition within 30 days or it reduces the averaged score. The plan that screens least aggressively carries the smallest follow-up burden.
Population mix compounds it in the same direction. D-SNP plans serving dual-eligible members can expect positive rates of 25% or higher, and C-SNP plans with cardiovascular and diabetes populations sit at 15% to 25% against roughly 10% for standard MA plans with healthier enrollment. The plans serving the highest-need populations therefore face the largest follow-up volumes, in many of the same counties where capacity is thinnest: HRSA data puts over 160 million Americans in designated mental health shortage areas, which would need roughly 8,000 additional practitioners to meet existing demand before this measure adds any volume at all.
The timing gives no room to solve it incrementally either. Data collection begins January 1, 2027, roughly seven months after the rule takes effect, and the resulting bonus payments arrive in CY 2031. Plans commit screening infrastructure, network capacity and care coordination staff against a return nearly five years out, with no historical performance data on this measure to anchor the projection.
Further Reading on actuary.info
- CMS Star Ratings Shift to 65% Clinical Weight in 2027: Score forecasting methodology under the restructured measure set, including the clinical investment sequencing framework for plans at the 3.5-to-4.0 star threshold.
- Star Ratings Overhaul Sends $18.6 Billion to MA Insurers Over the Next Decade: Full fiscal impact analysis of the CY 2027 final rule, the 11 removed measures, Health Equity Index reversal, and quality bonus payment mechanics behind the $18.56 billion estimate.
- Medicare Advantage Plan Exits Force 3 Million to Switch in 2026: How Star Ratings volatility and V28 revenue compression produced the largest disenrollment wave in MA history, with implications for the plans absorbing those members.
- CMS 2027 MA Final Rule: 2.48% Rate Notice Decomposition: Component walk of the effective growth rate, normalization, and coding pattern changes underlying the rate backdrop for this Star Ratings analysis.
- MHPAEA Data Rules Force MH/SUD Pricing Rethink for 2026 Plans: The parallel regulatory pressure on behavioral health parity compliance, including NQTL data evaluation requirements and the 2.6% plan-level cost impact from parity gap remediation.
Sources
- CMS: Contract Year 2027 Medicare Advantage and Part D Final Rule Fact Sheet
- CMS: Finalizes 2027 Medicare Advantage and Part D Payment Policies
- Reed Smith: CMS Makes Structural Changes to Star Ratings System
- Crowell & Moring: CMS Finalizes CY 2027 Medicare Advantage and Part D Rule
- Becker's Payer: CMS Finalizes 2027 Medicare Advantage and Part D Rule: 10 Notes
- Healthcare Finance News: CMS Finalizes Star Ratings Changes
- Press Ganey: CMS Just Ignited the Biggest Stars Shake-Up in a Decade
- USPSTF: Screening for Depression and Suicide Risk in Adults (2023 Recommendation)
- ASPE: Behavioral Health Prevalence, Utilization, and Spending Among Older Adult Medicare Beneficiaries
- CMS QPP: Quality Measure #134 (NQF 0418) Screening for Depression and Follow-Up Plan
- NCQA: HEDIS Depression Measures Specified for Electronic Clinical Data
- HRSA: Health Professional Shortage Areas Data
- KFF: Mental Health and Substance Use Disorder Coverage in Medicare Advantage Plans